Top of the morning to you, and a fine one it is. Despite a looming tropical storm and gloomy skies hovering over the Pharmalot campus, our spirits are sunny today. And why not? As the Morning Mayor taught us: Every day should be unwrapped like a precious gift. We often note this little insight, because a pick-me-up can be a good thing, especially in times such as these. Meanwhile, here are a few items of interest to help you start your day. Hope all goes well and do stay in touch. Remember, we accept saucy tips and dossiers. …

Regeneron Pharmaceuticals (REGN) says its Covid-19 antibody drug combination prevented and treated the virus in rhesus macaques and hamsters, Reuters writes. The animal study, which has not yet been peer-reviewed, found the cocktail of two monoclonal antibodies was able to “almost completely block establishment of virus infection.” The cocktail also minimized infection in a second study in which animals were infected with a higher level of the virus, but the prophylactic effect was greatly diminished with a lower dose.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy